Things could hardly have gone worse for healthcare investors in 2023. While shares of Eli Lilly and Novo Nordisk rocketed amid excitement about their new.
Novo Nordisk and Eli Lilly
both expect juggernaut sales for their diabetes and
weight-loss drugs to extend into coming years - limited only by
their availability. The two companies have.
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.